NervGen Pharma (TSE:NGEN) has released an update. NervGen Pharma is nearing the completion of enrollment for its Phase 1b/2a clinical trial of ...

"During the quarter we continued to benefit from our recruitment initiatives to attract study participants into our Phase 1b/2a clinical trial," said Mike Kelly, NervGen's President & CEO. "We ...

Detailed price information for Nervgen Pharma Corp (NGENF) from The Globe and Mail including charting and trades.

DelveInsight's 'Multiple Sclerosis Pipeline Insight 2024' report provides comprehensive global coverage of pipeline multiple ...

Multiple sclerosis (MS) is a chronic neurological disorder affecting the central nervous system (CNS), particularly the brain, spinal cord, and optic nerves. Continuous research has led to new drug ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Vancouver, British Columbia--(Newsfile Corp. - November 7, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated... "Lorem ipsum dolor sit amet, ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.

Vivek Ramaswamy reacted to a list of unnecessary government expenditures that included $33 million of government expenditure to run 'Monkey Island' in South Carolina; $549K to a Russian lab ...

Trump Taps Matt Gaetz for Attorney General, a Provocative Move President-elect Trump plans to nominate the Florida congressman, among a flurry of personnel announcements as Republicans neared ...